1. Scrip
  2. >>Business
  3. >>Deals

Merck Takes Over Orion-Partnered Prostate Cancer Drug MK-5684

 
• By Alaric DeArment

Deal Snapshot: Merck said it would pay potentially more than $1.6bn for an exclusive global license for opevesostat for metastatic castrate-resistant prostate cancer.

• Source: Shutterstock

Who: Merck & Co./Orion

What: The two companies are updating an agreement for the development of MK-5684/ODM-208 (opevesostat) from a collaboration involving co-development and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 
• By Jessica Merrill

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Roche Keen To Cut Out The Middle Men On US Pricing

 
• By Kevin Grogan

The Swiss giant has been talking to the US government about selling medicines directly to patients.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.